Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.

@article{Postlewait2016OutcomesOA,
  title={Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.},
  author={Lauren McLendon Postlewait and Cecilia G Ethun and Thuy B. Tran and Jason D. Prescott and Timothy M Pawlik and Tracy S. Wang and Jason A. Glenn and Ioannis S Hatzaras and Rivfka Shenoy and John E. Phay and Kara M. Keplinger and Ryan Courtney Fields and Linda X. Jin and Sharon M. Weber and Ahmed I. Salem and Jason Sicklick and Shady Gad and Adam Charles Yopp and John C. Mansour and Q. Y. Duh and Natalie Seiser and Carmen C. Sol{\'o}rzano and Colleen M. Kiernan and Konstantinos Ioannis Votanopoulos and E. A. Levine and Charles A. Staley and George A. Poultsides and Shishir Kumar Maithel},
  journal={Journal of the American College of Surgeons},
  year={2016},
  volume={222 4},
  pages={
          480-90
        }
}
BACKGROUND Current treatment guidelines recommend adjuvant mitotane after resection of adrenocortical carcinoma with high-risk features (eg, tumor rupture, positive margins, positive lymph nodes, high grade, elevated mitotic index, and advanced stage). Limited data exist on the outcomes associated with these practice guidelines. STUDY DESIGN Patients who underwent resection of adrenocortical carcinoma from 1993 to 2014 at the 13 academic institutions of the US Adrenocortical Carcinoma Group… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 19 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…